Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Launches Pancreatic Cancer Advisory Board
December 19, 2024 08:00 ET | Immuneering Corporation
Immuneering Launches Pancreatic Cancer Advisory Board
finacialnews-logo-final-01 (2).png
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
December 18, 2024 08:45 ET | FN Media Group LLC
PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by...
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
December 17, 2024 08:00 ET | Immuneering Corporation
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
November 27, 2024 08:00 ET | Immuneering Corporation
Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024 16:05 ET | Immuneering Corporation
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
logo.png
Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
November 11, 2024 08:00 ET | Autonomix Medical, Inc.
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6...
Picture1
Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction
October 31, 2024 08:00 ET | Autonomix Medical, Inc.
79% responder rate achieved with zero opioid use and quality of life improvement at 7 days post-procedure Company reaches 60% enrollment with 15 patients1 successfully enrolled; No unexpected...
Picture1.jpg
ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS
October 28, 2024 08:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that...
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 15, 2024 08:00 ET | Immuneering Corporation
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Transparency Market Research
Molecular Oncology Market Size is projected to Reach USD 7.4 billion, Garnering an 11.0% by 2034: Transparency Market Research Inc.
October 11, 2024 08:41 ET | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The global molecular oncology market (분자종양학 시장) was projected to attain US$ 2.3 billion in...